



TO: Executive Committee
FR: Helen Burstin, Chief Scientific Officer
Marcia Wilson, Senior Vice President, Quality Measurement
RE: Ratification of Measures for the Behavioral Health Consensus Development Project, Phase 3
DA: February 24, 2015

ACTION REQUESTED

The Executive Committee is asked to ratify the CSAC's recommendation to endorse measures for the current phases of the Behavioral Health project. We have listed below all of the recommended measures approved by the membership and the CSAC.

Measures Evaluated:

1. Behavioral Health Phase 3

The Behavioral Health Phase 3 [Standing Committee](#) evaluated 18 measures: 13 new measures and five measures undergoing maintenance review against NQF's standard measure evaluation criteria. Prior to committee evaluation, 17 measures were withdrawn from consideration at the request of the measure developers.

Consensus Process

Standing Committee: Sixteen measures are recommended for endorsement; one eMeasure was recommended for eMeasure trial use. The optional path of Trial Measure Approval is intended for eMeasures that are ready for implementation but cannot yet be adequately tested to meet NQF endorsement criteria. Measure # 0722: Pediatric Symptom Checklist (PSC), developed by Massachusetts General Hospital, was not recommended because the measure requires significant revision and should be resubmitted in the future.

Member Voting: A total of 14 member organizations voted on the measures. All of the recommended measures were approved, with 50 percent approval or higher by the councils. No votes were received from the Public/Community Health Agency and Supplier/Industry Councils.

CSAC: CSAC approved the Standing Committee's recommendation for endorsement of 16 measures and one eMeasure for trial use. Nine of the newly endorsed measures reflect diabetes and cardiovascular risk reduction for the high risk subpopulation of people with serious mental illness. CSAC did not recommend continued endorsement of Measure # 0722: Pediatric Symptom Checklist (PSC). The CSAC memo and member voting results for this project may be accessed at this [link](#); the project report may be accessed at this [link](#).

Measures Recommended:

- [Measure # 0710 Depression Remission at Twelve Months](#): Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at twelve

months defined as a PHQ-9 score less than 5. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment.

- [Measure # 0711 Depression Remission at Six Months](#): Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at six months defined as a PHQ-9 score less than 5. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment.
- [Measure # 0712 Depression Utilization of the PHQ-9 Tool](#): Adult patients age 18 and older with the diagnosis of major depression or dysthymia who have a PHQ-9 tool administered at least once during the four month measurement period.
- [Measure # 1365 Child and Adolescent Major Depressive Disorder \(MDD\): Suicide Risk Assessment](#): Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk.
- [Measure # 0108 Follow-Up Care for Children Prescribed ADHD Medication \(ADD\)](#): The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which is within 30 days of when the first ADHD medication was dispensed.
- [Measure # 2599 Alcohol Screening and Follow-up for People with Serious Mental Illness](#): The percentage of patients 18 years and older with a serious mental illness, who were screened for unhealthy alcohol use and received brief counseling or other follow-up care if identified as an unhealthy alcohol user.
- [Measure # 2600 Tobacco Use Screening and Follow-up for People with Serious Mental Illness or Alcohol or Other Drug Dependence](#): The percentage of patients 18 years and older with a serious mental illness or alcohol or other drug dependence who received a screening for tobacco use and follow-up for those identified as a current tobacco user.
- [Measure # 2601 Body Mass Index Screening and Follow-Up for People with Serious Mental Illness](#): The percentage of patients 18 years and older with a serious mental illness who received a screening for body mass index and follow-up for those people who were identified as obese (a body mass index greater than or equal to 30 kg/m²).
- [Measure # 2602 Controlling High Blood Pressure for People with Serious Mental Illness](#): The percentage of patients 18-85 years of age with serious mental illness who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled during the measurement year.
- [Measure # 2603 Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c \(HbA1c\) Testing](#): The percentage of patients 18-75 years of age with a serious mental illness and diabetes (type 1 and type 2) who had hemoglobin A1c (HbA1c) testing during the measurement year.
- [Measure # 2604 Diabetes Care for People with Serious Mental Illness: Medical Attention for Nephropathy](#): The percentage of patients 18-75 years of age with a serious mental illness and diabetes (type 1 and type 2) who received a nephropathy screening test or had evidence of nephropathy during the measurement year.
- [Measure # 2605 Follow-up after Discharge from the Emergency Department for Mental Health or Alcohol or Other Drug Dependence](#): The percentage of discharges for patients 18 years of age and older who had a visit to the emergency department with a primary diagnosis of mental health or

alcohol or other drug dependence during the measurement year AND who had a follow-up visit with any provider with a corresponding primary diagnosis of mental health or alcohol or other drug dependence within 7- and 30-days of discharge.

- [Measure # 2606 Diabetes Care for People with Serious Mental Illness: Blood Pressure Control \(<140/90 mm Hg\)](#): The percentage of patients 18-75 years of age with a serious mental illness and diabetes (type 1 and type 2) whose most recent blood pressure (BP) reading during the measurement year is <140/90 mm Hg.
- [Measure # 2607 Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c \(HbA1c\) Poor Control \(>9.0%\)](#): The percentage of patients 18-75 years of age with a serious mental illness and diabetes (type 1 and type 2) whose most recent HbA1c level during the measurement year is >9.0%.
- [Measure # 2608 Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c \(HbA1c\) Control \(<8.0%\)](#): The percentage of patients 18-75 years of age with a serious mental and diabetes (type 1 and type 2) whose most recent HbA1c level during the measurement year is <8.0%.
- [Measure # 2609 Diabetes Care for People with Serious Mental Illness: Eye Exam](#): The percentage of patients 18-75 years of age with a serious mental illness and diabetes (type 1 and type 2) who had an eye exam during the measurement year.

Measure(s) Approved for eMeasure Trial Use:

- [Measure # 2597 Substance Use Screening and Intervention Composite](#): Percentage of patients aged 18 years and older who were screened at least once within the last 24 months for tobacco use, unhealthy alcohol use, nonmedical prescription drug use, and illicit drug use AND who received an intervention for all positive screening results.

Measure(s) Not Recommended:

- [Measure # 0722 Pediatric Symptom Checklist \(PSC\)](#): The Pediatric Symptom Checklist (PSC) is a brief parent-report questionnaire that is used to assess overall psychosocial functioning in children from 3 to 18 years of age.